| 000 | 00000nam##2200000za#4500 |
| 001 | 9.573957 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210624183941 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150406|2001||||xxc|||||o f|0| 0 eng|d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH42-2/67-18-2000E-PDF |
|---|
| 110 | 1 |aCanada.|bHealth Canada. |bTherapeutic Products Programme. |
|---|
| 245 | 10|aViral safety evaluation of biotechnology products derived from cell lines of human or animal origin |h[electronic resource] |
|---|
| 260 | |aOttawa - Ontario : |bHealth Canada. |cJanuary 5, 2001, c2000. |
|---|
| 300 | |a39p.|bglossary, tables |
|---|
| 490 | 1 |aGuidance for industry |vICH Topic Q5A |
|---|
| 590 | |a12-21-Supp|b2012-05-18 |
|---|
| 690 | 07|aBiotechnology|2gcpds |
|---|
| 690 | 07|aContamination|2gcpds |
|---|
| 690 | 07|aBiochemical products|2gcpds |
|---|
| 775 | 08|tÉvaluation de la sécurité virologique des produits issus de la biotechnologie et dérivés de lignées cellulaires d'origine humaine ou animale |w(CaOODSP)9.603927 |
|---|
| 776 | 0#|tViral safety evaluation of biotechnology products derived from cell lines of human or animal origin / |w(CaOODSP)9.615261 |
|---|
| 830 | #0|aGuidance for industry ;|vICH Topic Q5A|w(CaOODSP)9.506921 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s119 KB|uhttps://publications.gc.ca/collections/Collection/H42-2-67-18-2000E.pdf|yICH Topic Q5A |
|---|